Cipal said it intends to acquire Avenue Therapeutics, Inc, a Fortress Biotech company, in two stages.
Cipla’s subsidiary to acquire US-based Avenue Therapeutics for $ 215 million
More from Industry NewsMore posts in Industry News »
- Bausch, Clearside receive U.S. approval for eye injection
- Priority list being drawn up of kids with comorbidities for vaccine rollout
- Namibia halts use of Sputnik jabs after South Africa HIV fears
- We are waiting for DCGI approval for children’s Covid-19 vaccine: Bharat Biotech Chairman
- Covid-19: ICMR and task force stress on completing adult vaccination